Axon Enterprise, Inc (NASDAQ:AXON) Position Increased by Jennison Associates LLC

Jennison Associates LLC boosted its position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 23,203.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 614,053 shares of the biotechnology company's stock after buying an additional 611,418 shares during the period. Jennison Associates LLC owned 0.79% of Axon Enterprise worth $322,961,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in AXON. Kingsview Wealth Management LLC grew its holdings in shares of Axon Enterprise by 14.0% during the first quarter. Kingsview Wealth Management LLC now owns 406 shares of the biotechnology company's stock worth $214,000 after buying an additional 50 shares during the last quarter. Bailard Inc. grew its holdings in shares of Axon Enterprise by 15.9% during the first quarter. Bailard Inc. now owns 466 shares of the biotechnology company's stock worth $245,000 after buying an additional 64 shares during the last quarter. Graypoint LLC grew its holdings in shares of Axon Enterprise by 9.2% during the first quarter. Graypoint LLC now owns 474 shares of the biotechnology company's stock worth $249,000 after buying an additional 40 shares during the last quarter. Ascent Wealth Partners LLC grew its holdings in shares of Axon Enterprise by 2.4% during the first quarter. Ascent Wealth Partners LLC now owns 14,508 shares of the biotechnology company's stock worth $7,630,000 after buying an additional 335 shares during the last quarter. Finally, Bridgewater Advisors Inc. purchased a new position in shares of Axon Enterprise during the first quarter worth about $434,000. Institutional investors and hedge funds own 79.08% of the company's stock.

Insider Buying and Selling at Axon Enterprise

In related news, President Joshua Isner sold 9,905 shares of the stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $738.03, for a total transaction of $7,310,187.15. Following the sale, the president owned 298,809 shares in the company, valued at $220,530,006.27. This represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CRO Cameron Brooks sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $740.76, for a total transaction of $2,222,280.00. Following the completion of the sale, the executive owned 19,447 shares in the company, valued at $14,405,559.72. The trade was a 13.36% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,642 shares of company stock valued at $30,500,428. Corporate insiders own 4.40% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Wolfe Research initiated coverage on Axon Enterprise in a report on Monday, July 7th. They issued an "outperform" rating on the stock. UBS Group initiated coverage on shares of Axon Enterprise in a research report on Wednesday. They set a "neutral" rating and a $820.00 price target for the company. Barclays lifted their price target on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Needham & Company LLC lifted their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Finally, Bank of America lifted their price target on shares of Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a research report on Wednesday, June 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Axon Enterprise currently has a consensus rating of "Moderate Buy" and an average target price of $763.75.

Axon Enterprise Trading Up 1.4%

Shares of AXON stock traded up $10.23 on Friday, reaching $756.09. 404,179 shares of the stock were exchanged, compared to its average volume of 602,176. The stock has a market cap of $58.86 billion, a P/E ratio of 182.63, a price-to-earnings-growth ratio of 87.03 and a beta of 1.29. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68. The firm has a 50 day moving average of $763.54 and a two-hundred day moving average of $645.97. Axon Enterprise, Inc has a 1-year low of $279.02 and a 1-year high of $830.21.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The company had revenue of $603.63 million for the quarter, compared to analysts' expectations of $585.67 million. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The firm's quarterly revenue was up 31.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.15 earnings per share. On average, research analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.